Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KORU Medical Systems (KRMD) Cash & Current Investments (2020 - 2025)

KORU Medical Systems (KRMD) has disclosed Cash & Current Investments for 11 consecutive years, with $8.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Current Investments fell 3.89% to $8.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.5 million, a 3.89% decrease, with the full-year FY2024 number at $9.6 million, down 16.56% from a year prior.
  • Cash & Current Investments was $8.5 million for Q3 2025 at KORU Medical Systems, up from $8.1 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $26.8 million in Q1 2021 to a low of $8.1 million in Q2 2025.
  • A 5-year average of $15.3 million and a median of $11.7 million in 2023 define the central range for Cash & Current Investments.
  • Peak YoY movement for Cash & Current Investments: surged 260.47% in 2021, then crashed 45.85% in 2023.
  • KORU Medical Systems' Cash & Current Investments stood at $25.3 million in 2021, then plummeted by 31.29% to $17.4 million in 2022, then tumbled by 34.04% to $11.5 million in 2023, then fell by 16.56% to $9.6 million in 2024, then fell by 11.66% to $8.5 million in 2025.
  • Per Business Quant, the three most recent readings for KRMD's Cash & Current Investments are $8.5 million (Q3 2025), $8.1 million (Q2 2025), and $8.7 million (Q1 2025).